CAS
CBIO

CTC Alternative Strategies’s Crescent Biopharma CBIO Stock Holding History

CTC Alternative Strategies’s Portfolio CBIO Stock Details CBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-177
Closed -$53.1K – 218
2024
Q1 		$53.1K Buy
+177
New +$52.9K 0.03% 113

Other funds holding CBIO

BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

CTC Alternative Strategies's CBIO Position: Q2 2024 in Review

CTC Alternative Strategies sold out of Crescent Biopharma (CBIO) in Q2 2024, closing a stake of 177 shares — an estimated $53.1K sold.

CTC Alternative Strategies first reported a position in CBIO in Q1 2024 and held it in 1 quarter. The position peaked at $53.1K in Q1 2024. 35 funds tracked by Wall St. Rank hold CBIO as of Q2 2024.

  • CTC Alternative Strategies reported no remaining Crescent Biopharma position as of Q2 2024 after selling out during the quarter.
  • CTC Alternative Strategies sold 177 Crescent Biopharma shares in Q2 2024, an estimated $53.1K.
  • CTC Alternative Strategies first reported a position in Crescent Biopharma in Q1 2024 and held it in 1 quarter.
  • CTC Alternative Strategies's Crescent Biopharma position peaked at $53.1K in Q1 2024.
  • 35 funds tracked by Wall St. Rank held Crescent Biopharma as of Q2 2024.

Based on CTC Alternative Strategies's 13F filing for Q2 2024, filed 2 Aug 2024.